The receptor activator of NF‐κB ligand‐osteoprotegerin system in pulpal and periapical disease

By  

INTERNATIONAL ENDODONTIC JOURNAL, Vol. 46, Iss. 2, 2013-02 ,pp. : 99-111

John Wiley & Sons Inc

Access to resources Recommend Favorite

Serum osteoprotegerin and receptor activator of nuclear factor-κB ligand (RANKL) concentrations in allogeneic stem cell transplant-recipients: a role in bone loss?

By Kananen K.   Volin L.   Laitinen K.   Ruutu T.   Välimäki M.  

Osteoporosis International, Vol. 17, Iss. 5, 2006-05 ,pp. : 724-730

Springer Publishing Company

Access to resources Recommend Favorite

An ethanol root extract of Cynanchum wilfordii containing acetophenones suppresses the expression of VCAM-1 and ICAM-1 in TNF-α-stimulated human aortic smooth muscle cells through the NF-κB pathway

By                  

International Journal of Molecular Medicine, Vol. 35, Iss. 4, 2015-01 ,pp. : 915-924

Spandidos Publications

Access to resources Recommend Favorite

Preoperative Serum Receptor Activator of Nuclear Factor-κB Ligand/Osteoprotegerin Predict Stabilization of Spontaneously Restored Sinus Rhythm in Persistent Atrial Fibrillation Patients after Mitral Valve Surgery

By  

Cardiology, Vol. 127, Iss. 3, 2014-01 ,pp. : 183-189

Karger

Access to resources Recommend Favorite

Levels of osteoprotegerin (OPG) and receptor activator for nuclear factor kappa B ligand (RANKL) in serum: Are they of any help?

By Wagner Doris  

Wiener Medizinische Wochenschrift, Vol. 160, Iss. 17-18, 2010-09 ,pp. : 452-457

Springer Publishing Company

Access to resources Recommend Favorite